Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Allena Pharmaceuticals, Inc. (NASDAQ: ALNA).

Full DD Report for ALNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALNA)

Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
-- Initiated Phase 3 Study URIROX-1™ and Phase 2 Study 206 for ALLN-177 in Patients with Severe Hyperoxaluria -- -- Reiterates Guidance for Key Objectives Across Portfolio-- NEWTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Stocks To Watch: Apple, FOMC And China On Tap
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. U.S. Treasury Secretary Steven Mnuchin is scheduled to lead a delegation to China f...
Source: SeekingAlpha
Date: April, 28 2018 09:13
Midday Gainers / Losers (04/06/2018)
Gainers: NVCN +56% . LFIN +47% . OGEN +29% . BWEN +25% . CASI +16% . FORD +14% . MBII +10% . ABIL +10% . GEN +10% . TNTR +9% . More news on: Neovasc Inc., LongFin Corp, Oragenics, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 06 2018 12:36
Midday Gainers / Losers (4/3/2018)
Gainers: MYND +66% . BPTH +33% . EBIO +23% . INNT +22% . ALNA +19% . CASI +19% . SSC +18% . URGN +18% . CLLS +17% . REFR +13% . More news on: MYnd Analytics, Inc., Bio-Path Holdings, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more .....
Source: SeekingAlpha
Date: April, 03 2018 12:45
Midday Gainers / Losers (4/2/2018)
Gainers: SLS +167% . SSC +23% . MNOV +21% . ALNA +18% . MARK +15% . BLFS +15% . MBII +14% . CASI +12% . TCON +12% . CHCI +12% . More news on: SELLAS Life Sciences Group, Inc., Seven Stars Cloud Group, Inc., MediciNova, Inc., Stocks on the move, , Read m...
Source: SeekingAlpha
Date: April, 02 2018 12:45
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
 -- Initiated URIROX-1™, First Phase 3 Trial of ALLN-177 in Enteric Hyperoxaluria; Topline Data Expected in Second Half of 2019 – -- Initiated Phase 2 Trial of ALLN-177 for Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Hyperoxalemia -- -- Init...
Source: GlobeNewswire
Date: March, 27 2018 08:00
U.S. Biotech/Pharma Sector Daily Observations Letter: March 12, 2018
There was a small pullback in the U.S. equity indexes today. VIX was up more than 7% as investor hedged their portfolios ahead of the inflation, CPI data which will be released tomorrow at 8.30 am. IBB data by YCharts Esperion ( ESPR ) was volatile today after the release of cardiovas...
Source: SeekingAlpha
Date: March, 13 2018 03:58
3 Things In Biotech, March 8: A Tale Of 3 New Trials
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Sea...
Source: SeekingAlpha
Date: March, 09 2018 08:00
Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
NEWTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney dis...
Source: GlobeNewswire
Date: March, 07 2018 08:00
Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
URIROX-1 TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population -    Topline Data Expected in Second Half of 2019  - ALLN-177 has Potential to be the First FDA-Approved Treatment for Enteric Hyperoxaluria - NEWTON, Mas...
Source: GlobeNewswire
Date: March, 06 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1716.1516.0016.6015.8644418,624

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-178491,74448.6812Short
2018-08-161,3242,98344.3848Short
2018-08-159,48020,08147.2088Short
2018-08-145,97316,94735.2452Short
2018-08-1310,06013,91672.2909Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALNA.


About Allena Pharmaceuticals, Inc. (NASDAQ: ALNA)

Logo for Allena Pharmaceuticals, Inc. (NASDAQ: ALNA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALNA)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 25 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 27 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 27 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: ALNA)

      Daily Technical Chart for (NASDAQ: ALNA)


      Stay tuned for daily updates and more on (NASDAQ: ALNA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALNA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALNA and does not buy, sell, or trade any shares of ALNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/